Home > Insider Trading > Filing (0001209191-19-019994)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1300699	Athenex Inc.	ATNX	Pharmaceutical Preparations (2834)	431985966

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1708966	Sheldon Trainor-Degirolamo	C/O Athenex, Inc. 1001 Main Street, Suite 600 Buffalo NY 14203		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-03-14	6	$11.79	665,412	No	4	S	Indirect	By PacBridge Partners V Investment Co Ltd.
Common Stock	Disposition	2019-03-15	54,079	$11.77	611,333	No	4	S	Indirect	By PacBridge Partners V Investment Co Ltd.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By PacBridge Partners V Investment Co Ltd.
No	4	S	Indirect	By PacBridge Partners V Investment Co Ltd.

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$11.00	2027-06-13	19,500	19,500	Direct
Common Stock	Stock Option (Right to Buy)	$17.30	2028-03-27	19,500	19,500	Direct
Common Stock	Stock Option (Right to Buy)	$13.17	2029-02-28	17,500	17,500	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2027-06-13	19,500	19,500	Direct
2028-03-27	19,500	19,500	Direct
2029-02-28	17,500	17,500	Direct

Footnotes

These shares are held for the account of PacBridge Partners V Investment Co Ltd. Sheldon Trainor-Degirolamo ("Mr. Trainor-Degirolamo") is the sole director and shareholder of PacBridge Partners V Investment Co Ltd. and has sole voting and dispositive power over the shares held by it.
Mr. Trainor-Degirolamo disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Trainor-Degirolamo is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This transaction was executed in multiple trades ranging from $11.75 to $11.85. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected.
The option vests in four equal annual installments beginning on June 13, 2018.
This option vests in four equal annual installments beginning on March 27, 2019.
The option vests in four equal annual installments beginning on February 28, 2020.